骨桥蛋白与垂体腺瘤侵袭性的相关性研究
|
摘要
背景 垂体腺瘤是临床常见的肿瘤，约占颅内肿瘤的10％左右。组织病理学表明，垂体腺瘤是良性肿瘤。但是，部分的垂体腺瘤呈现出恶性的生物学行为，即侵袭性垂体腺瘤。侵袭性垂体腺瘤指腺瘤生长突破包膜并侵犯邻近结构，如硬膜、颅骨、神经、海绵窦或者包绕颈内动脉。垂体腺瘤的侵袭性导致很高的术后肿瘤残余和复发。垂体腺瘤的侵袭性是目前针对垂体腺瘤研究的热点和难点。OPN(osteopontin，骨桥蛋白)是一种磷酸化的分泌蛋白。OPN的受体包括整合素以及CD44。近年来研究表明，OPN与很多肿瘤的浸润、转移、瘤体大小等有关，是一种新的肿瘤标志物。关于OPN在垂体腺瘤侵袭过程中的作用目前尚无研究报道。本研究试图阐明OPNmRNA在垂体腺瘤的表达情况，OPN及其主要受体整合素α_vβ_3的表达，OPNmRNA与垂体腺瘤生长速度的关系，整合素α_v β_3的表达与OPN的关系。
方法 自2004年3月至2005年11月共收集78例患者的垂体腺瘤手术标本及临床资料，其中侵袭性垂体腺瘤37例，非侵袭性腺瘤41例。FQ-PCR(Fluorescence quantitative polymerase chain reaction，荧光定量PCR)技术检测垂体腺瘤OPN mRNA，免疫组织化学S-P法检测OPN及整合素α_v β_3的表达，观察OPN mRNA及其蛋白的表达与垂体腺瘤侵袭性的关
Backgroud Pituitary adenomas is a common tumor in clinical works, and is about 10% of intracranial tumors. Histopathology proved pituitary adenomas is a benign tumor. But some of the tumor appearing aggressive biological behavior, is so called invasive pituitary adenomas. Invasive pituitary adenomas tend to break through the capsule and invase into the neighbour structure such as dura, nerve, bone, cavernous sinus and even internal carotid. The invasiveness of pituitary adenomas lead to high recurrency and residucy. Now the invasiveness is the hot topic and nodus on pituitary adenomas. Osteopontin ( OPN ) is a secreted phosphate-protein. Its' receptor including integrin and CD44 . Study shows that OPN is related to many tumors on invasion, metastasis, and even the tumor volume. We find no report and study about OPN on the invasiveness of pituitary adenomas. In this study we have investigated the expression of OPN mRNA and OPN protein in pituitary adenomas, the relationship
方法 自2004年3月至2005年11月共收集78例患者的垂体腺瘤手术标本及临床资料，其中侵袭性垂体腺瘤37例，非侵袭性腺瘤41例。FQ-PCR(Fluorescence quantitative polymerase chain reaction，荧光定量PCR)技术检测垂体腺瘤OPN mRNA，免疫组织化学S-P法检测OPN及整合素α_v β_3的表达，观察OPN mRNA及其蛋白的表达与垂体腺瘤侵袭性的关
Backgroud Pituitary adenomas is a common tumor in clinical works, and is about 10% of intracranial tumors. Histopathology proved pituitary adenomas is a benign tumor. But some of the tumor appearing aggressive biological behavior, is so called invasive pituitary adenomas. Invasive pituitary adenomas tend to break through the capsule and invase into the neighbour structure such as dura, nerve, bone, cavernous sinus and even internal carotid. The invasiveness of pituitary adenomas lead to high recurrency and residucy. Now the invasiveness is the hot topic and nodus on pituitary adenomas. Osteopontin ( OPN ) is a secreted phosphate-protein. Its' receptor including integrin and CD44 . Study shows that OPN is related to many tumors on invasion, metastasis, and even the tumor volume. We find no report and study about OPN on the invasiveness of pituitary adenomas. In this study we have investigated the expression of OPN mRNA and OPN protein in pituitary adenomas, the relationship
引文
1. Agrawal D, etal. Osteopontin identified as colon cancer tumor progr-ession marker [J]. C R Biol. 2003; 326(10-11): 1041-1043.
2. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins[J].Cell. 1979; 16(4):885-893.
3. Senger DR, Wirth DF, Hynes R0. Transformation-specific secreted phosphoproteins[J]. Nature. 1980; 286(5773):619-621.
4. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein(osteopontin) cDNA reveals an Arg-Gly-Asp cell binding sequence[J]. Proc Natl Acad Sci USA. 1986; 83(23): 8819-8823.
5. Coppola D, Correlation of osteopontin protein expression and path — ological stage across a wide variety of tumorhistologies [J]. Clin Cancer Res. 2004 ; 10(1Pt1): 184-190.
6. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clini—cal and experimental studies[J]. J Mammary Gland Biol Neoplasia. 2001;6 (4) :419-429.
7. Ue T, Yokozaki H, Kitadai Y, etal. Co-expression of osteopontin and CD44v9 in gastric cancer[J].Int J Cancer. 1998;79 (2) :127-132.
8. Casson AG, Wilson SM, McCart JA, etal. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human eso — phageal cancer[J].Int J Cancer. 1997;72 (5) :739-745.
9. Thalmann GN,Sike RA, Devoll RE, etal.Osteopontin rpossible role in prostate cancer progress[J]. Clinical Cancer Res. 1999;5 (8) : 2271-2277.
10. Otte SJ, Winquist EW, Sititt L, etal. Plasma osteopontin associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma[J] .Cancer. 2002;95(3): 506-512。
11. Furger KA, Menon RK, Tuckl AB, etal. The functional and clinical roles of osteopontin in cancer and metastasis[J].Curr Ml Med.2001; 1(5): 621-632.
12. Tuck AB, O' Malley FP,Singhal H, etal. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas [J]. Arch Pathol Lab Med. 1997; 121(6):578-584.
13. Ye QH,Qin LX, Forgues M, etal. Predicting bepatitis B vinus-positive metastatic hepatocellular carcinomas using gene expression prof- iling and supervised machine learning[J]. Nature Med. 2003;9(4): 416-423.
14. Shijubo N, Uded T, Koo S, etal. Vascular endothelial growth factor and osteopontin in tumor biology[J].Crit Rev Oncog. 2000; 11 (2): 135-146.
15. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies[J].J Mammary Gland Biol Neoplasia. 2001;6(4):419-429.
16. Weinberger KM, Wiedenmann E, Bohm S,etal. Sensitive and accurate quan —titation of hepatitis B virus DNA using a kinetic fluorescence detection system(Taq Man PCR) [J]. J Virol Methods. 2000; 85 (1-2) : 75-82.
17. Eun AJ, Soeh M, Wong S, etal. Simultaneous quantitation of two orchid viruses by the Taq Man real-time RT-PCR[J]. J Virol Methods. 2000; 87 (1-2) : 151-160.
18．蒋春燕，王泰健，王琴。实时荧光定量PCR技术[J]。动物医学进展。2005：12 (1)：101—105。
1. Anderson RC, Grant JJ, de la Paz R, etal. Volumetric measurements in the detection of reduced ventricular volume in patients with normal pressure hydrocephalus whose clinical condition improved after ventriculoperitoneal shunt placement[J]. J Neurosurg.2002;97(1), 73-79.
2. Clatterbuck RE, Sipos EP. The efficient calculation of neurosurgically relevant volumes from computed tomographic scans using Cavalieri' s Direct Estimator[J]. Neurosurgery. 1997;40 (2) :339-343.
3. Medico E, Gentile A, Lo Celso C, etal. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth[J]. Cancer Res. 2001;61(15):5861-5868.
4. Shi jubo N, Uede T, Kon S, etal. Vascular endothelial growth factor and osteopontin in tumor biology[J].Crit Rev Oncog. 2000; 11(2): 135-146.
5. Denhardt DT, Chamber AF. Overcoming obstacles to metastasis defenses against host defences:osteopontin(OPN) as a shield against attack by cytotoxic host cells. J Cellular Biochem. 1994;56(1):48-51.
6. Vacca A, Ria R, Presta M, etal. Integrin alpha V beta 3 engagement modulates cell adehension, proliferation, and protease secretion in human lymphoid tumor cells[J]. Exp Hematol. 2001;29(8):993-1003.
7. Hotte S, Winquist EW, Stitt L, etal. Plasma osteopontin associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma[J]. Cancer. 2002; 95 (3) : 5. 6-512.
8．董俊峰，张占堆。51例颅内血肿量的新法计算探讨[J]。河南实用神经疾病杂志。2002：5 (2)：73-75．
9. Fucci MJ, Buchman CA, Brackmann DE, etal. Acoustic tumor growth: implica tions for treatment choices[J]. Am J Otol. 1999: 20 (4) : 495-499.
10. Tang Xi, HU Guoqing, Qiu Hong, etal. Comparing gross tumor volume of delineation between CT and MRI for nasopharygeal carcinoma[J]. The Chinese-German Journal of Clinical Oncology. 2005; 4 (3) : 141-145.
11. Thapar K, Kovacs K, Scheithauer BW, etal. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody[J]. Neurosurgery. 1996; 38 (1) : 99-106.
12. Honegger J, Prettin C, Feuerhake F, etal. Expression of Ki-67antigen in nonfunctioning pituitary adenomas: correl-ation with growth velocity and invasiveness[J]. J Neurosurgery. 2003; 99 (4) : 674-679.
13. Landolt AM, Shibata T, Kleihues P. Growth rate of human pituitary adenomas[J]. J Neurosurgery. 1987; 67 (6) : 803-806.
14. Lath R, Chacko G, Chandy MJ. Ditermination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody[J]. Neuro India. 2001; 49 (2) : 144-147.
15. Paez PM, Ledda MF, Goldberg V, et al. High levels of matrix metall oproteinases regulate proliferation and hormone secretion in pituitary cells [J]. J Clin Endocrinol Metab. 2000; 85 (1) : 263～269.
16．李玉斌，魏新亭，宋来君，等。基质金属蛋白酶-2和9在垂体腺瘤中表达[J]。中国临床神经外科杂志．2004：9 (6)：410-413．
17．刘卫平，章翔，松本义人，等。MMP-2及MMP-9表达在侵袭性垂体腺瘤中的生物学意义[J]。中华神经外科疾病研究杂．2004：3 (1)：47-51。
18. Hofmann UB, Westphal JR, Wass ET, etal. Coexpression of integrin alpha V beta 3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression[J]. J Invest Dermatol. 2000; 115 (4) : 625-632.
19. Silletti S, Kesster T, Goldberg J, etal. Disruption of matrix metalloproteinase 2 binding to integrin alpha V beta 3 by an organic molecule inhibites angiogenesis and tumor growth in vivo[J]. Proc Natl Acta Sci USA. 2001; 98 (1) : 119-124.
1. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy[J]. Biochim Biophys Acta. 2001; 1552(2): 61-85.
2. Furger KA, Alian AL, Wilson SM, etal. β_3 integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin[J].Mol Cancer Res. 2003;1(11): 810—819。
3. Liapis H, Flath A, Kitazawa S, etal. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases [J]. Diagn Mol Pathol. 1996; 5 (2): 127-135.
4. Hofmann UB, Westphal JR, Wass ET, etal. Coexpression of integrin alpha V beta 3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation:correlation with melanoma progression[J].J Invest Dermatol.2000;115(4):625-632.
5. Silletti S, Kesster T, Goldberg J, etal. Disruption of matrix metal1 oproteinase 2 binding to integrin alpha V beta 3 by an organic molecule inhibites angiogenesis and tumor growth in vivo[J].Proc Natl Acta Sci USA. 2001;98(1):119-124.
6. Liu W, Matsumoto Y, Okada M, etal. Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas[J].J Medical Investigation. 2005; 52(3-4): 151-158.
7. Paez PM,Ledda MF, Goldberg V, etal.High level of matrix metall oproteinases regulate proliferation and hormone secretion in pituitary cells[J]. J Clinical Endocrinology Metasbolism. 2000; 85(1): 263-269.
8. Khabit AM, Nip J, Fallavollita L, etal. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alpha V beta 3[J].Int Cance. 2001; 91(3) :300-308。
9. Mousa SA, Mohamed S, Wexler EJ, etal. Antiangiogenesis and anticancer efficacy of TA138, a novel alpha V beta 3 antagonist[J]. Anticancer Research. 2005;25(1A):197-206.
10. Paulus W, Baur I, Schupan D, etal. Characterization of integrin receptor in normal and neoplastic human brain[J].American journal of pathology. 1993;143(1):154-163.
1. Sodek J, Ganss B, Mckee MD. Osteopontin[J]. Crit Rev Oral Biol Med. 2000; 11 (3) : 279-303.
2. Chambers AF, Behrend EI, Wilson SM, etal. Induction of expression of osteopontin (OPN, secreted phosphoprotein) in metastatic, ras-transformed NIH 3t3 cells[J]. Anticancer Res. 1992; 12 (1) : 43-47.
3. Weber GF. The metastatic gene osteopontin: a candidate target for cancer therapy [J]. Biochim Biophys Acta. 2001; 1552 (2) : 61-85.
4. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cell signaling and toxicant injuring [J]. Annu Rev Pharmacol Toxical. 2001; 41 (5) : 723-749.
5. Crosby AH, Edwards SJ, Murray JC, etal. Genomic organization of the human osteopontin gene: exclusion of the locus from a causative role in the parhogenesis of dentinogenesis imperfecta type Ⅱ [J]. Genomics. 1995; 27 (1) : 155-160.
6. Sodek J, Zhu B, Huynh MH, etal. Novel functions of the matricellular proteins Osteopontin and osteonection/SPARC [J]. Connect Tisssue Res. 2002; 43 (2-3) : 308-319.
7. Haynes B, Teken M, Hale L, etal. CD44—a molecule involved in leukocyte asherence and T-cell activation[J]. Immunol Today. 1989; 10 (2) : 423-428.
8. Serenton G, Bell M, Jackson D, etal. Genomic structure of DNA encoding the lymphocyte homing receptor CD44reveals at least 12 alternatively spkiced exons[J]. Pro Natl Acad Sci USA. 1992; 89 (24) : 12160-12164.
9. Naor D, Sionov RV, Shalom DI. CD44: structure, function, and associatin with malignant process[J]. Adv Cancer Res. 1997; 71: 241-319.
10. Sneath R, Mangham D. The normal structure and function of CD44 and its role in neoplasia[J]. Mol Pathol. 1998; 51 (4) :191-200.
11．田文，张国华，谷志远，等。CD44异常表达与结肠直肠癌形成和转移的关系[J]。中华医学杂志。1997；77 (8)：72—73．
12. Ishida T. Immunohistochemical expression of the CD44variant 6 in colorectal adenocarcinoma[J]. Surh Today. 2000; 30 (1) : 28-32.
13. Ni HM, Leong AF, Cheong D, etal. Expression of CD44 variants in colorectal carcinoma quantified by real-time reverse transcriptasepolymerase chain reactin[J]. Lab Clin Med. 2002; 139 (1) : 59-65.
14. Koochekpour S, Pilkington G, Merzak A, etal. Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human gliomas cell in vitro[J]. Int J Cancer. 1995; 63 (3) : 450-454.
15. Kaai jk P, Troost D, Morsink F, etal. Expression of CD44 splice variants in human primary brain tumors[J]. J Neurooncol. 1995; 26 (3) : 185-190.
16. Li h, j Liu Hofmann M, etal. Differential CD44 expression paterns in primary tumors and brain metastasis[J]. Br J Cancer. 1995; 72 (1) : 160-163.
17．段波，赵红洋，李新建，等。细胞黏附分子CD44s，CD44v5在垂体腺瘤中的表达及其意义[J]。现代肿瘤医学。2005；13 (4)：466—468。
18. Frank S, Rihs HP, Stocker W, etal. Combined dectection of CD44 ISOFORMS BY EXON-SPECIFIC rt-PCR and immunohistochemistry in primary human brain tumors and brain metastases[J]. Biochem Biophys Res Commun. 1996; 222 (3) : 794—801。
19. Kuniyasu H, Chihara Y, Kubozoe T, etal. Co-expression of CD44v3 and heparanase is correlated with metastasis of human colon cancer [J]. Int J Mol Med. 2002; 10 (3) : 333-337.
20. Hamidi S, Salo T, Kainulainen T, etal. Expression of alpha (v) beta 6 integrin in oral leukoplakia[J]. Br J Cancer. 2000; 82 (8) : 1433-1440
21. Kim S, Bell K, Mousa SA, etal. Regulayion of angiogenesis in vivo byligation of integrin alpha 5 beta with the central cell-binding domain of fibronection[J]. Am J Pathol. 2000; 156 (4) : 1345-1362
22. Grooms SV, Terrsacio L, Jones LS, etal. Anatomical localization of beta 1 integrin-like immunoreactivity in rat brain[J]. Experimental Neurology. 1993;122(2):253-259.
23. Carloni V, Mazzocca A, Pantaleo P. etal. The integrin alpha 6 beta 1, is necessary for the matrix-dependeng activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells [J]. Hepatology. 2001; 34(1): 42-49.
24. Thomas GJ, Lewis MP, Whawell SA, etal. Expression of the alpha v beta 6 intefrin promtes migration and invasion in squamous carcinoma cell[J].J Invest Dermatol.2001;117(1):67-73.
25. Abdel-Ghany M, Cheng HC, Elble RC, etal. The breast cancer beata 4 integrin and endothelial heman CLC A2 mediated ;ing metastasis [J]. J Biol Chem.2001; 276(27):25438-25446.
26. Daemi N, Thomasset N, Lissitzky JC, etal. Anti-beta 4 integrin antibodies enhance migratory and invasive abilities of human colon adenocarcinomas cells and their MMP-2 expression[J]. Int J Cancer. 2000:85(6):850-856.
27. Kok RJ, Schraa AJ, Bassi R, etal. Preparation and functional evaluation of RDG-modified proteins as alpha (v) beta (3) integrin drectod therapeutics[J].Bioconjugate Chemistry. 2002;13(1):128-135.
28. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis [J]. Cancer Journal. 2000;6(suppl 3):245-249.
29. Humphries MJ. The molecular basis and specificity of integrin-ligand interactions[J].J Cell Sci. 1990;97(pt 47):585-592.
30. Zhang J, Takahashi K, Takahashi F,etal. Differential osteopontin expression in lung cancer[J].Cancer Lett.2001;171(2):215-222.
31. Tuck AB, Chambers AF. The role of osteopontin in breast cancer:clinical and experimental studies[J].J Mammary Gland Biol Neoplasis. 2001;6(4): 419-429.
32. Gotoh M, Sakamoto M, Kanetaka K, etal. Over expression of osteopontin in hepatocellular carcinomas[J].Pathol Int.2002;52(1):19-24.
33. Denhardt DT, Mistretta D, Chambers AF, etal. Transcriptional regulation of osteopontin and the metastatic phenotype:evidence for a ras-activated enhancer in the human OPN promoter[J].C1in Exp Metastasis. 2003;20(1):77-84.
34. Singhal H, Bautista DS, Tonkin KS, etal. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival[J].C1in Cncer Res. 1997;3(4):605-611.
35. Yeatman TJ, Chamber AF. Osteopontin and colon cancer progression [J]. Clin Exp Metastasis. 2003;20(1):85-90.
36. Hotte SJ, Winquist EW,Stitt L, etal. Plasm osteopontin associations with survival and metastasis to bone in mean with hormone-refractory prostate carcinoma. Cancer. 2002;95(3):506-512.
37. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metallo proteinase-2 activation through I kappa alpha/IKK signaling pathways, and curcumin(diferulolylmethane) down- regulates these pathways[J].J Biol Chem.2003;278(16):14487-14497.
38. Mahabeleshwar GHD, Kunda GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transaction in breat cancer cells[J].J Biol Chem.2004;279(12):11051-11064.
39. Coppola D, Szabo M, Boulware D. Correlatin of osteopontin protein expression and pathological atge across a wide variety of tumor histologies[J].Clin Cancer Res.2004;10(1):184-190.
40. Hotte SJ, Winquist EW, Stitt L, etal. Plasma osteopontin associations with survival and matastasis to bone in men with hormong-refractory prostate carcinoma[J]. Cancer. 2002;95(3):506-512.
41. Barry STMLudbrook SB, Murrison E, etal. A regulated intergration between alpha 5 beta 1 integrin and osteopontin[J]. Biochem Biophys Res Commun. 2000;267 (3); 764-769。
42. Katagiri YU.Sleeman J,Fujii H, etal.CD44 variants but not CD44s cooperated with beta 1-containing integrins to permit cell bind to osteopontin independ of argine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis[J]. Cancer Res. 1999; 59 (1) : 219-226.
1. Knosp E. Steiner E. Kitz K etal. Pituitary adenomas with invasion of the cavernoussinus space: A magnetic resonance imaging classification compared with surgical findings [J]. Neurosurgery. 1993; 33 (4) : 610-617
2. Miki Y, Maisuo M, Nishzawa S, etal. Pituitary adenomas and normal pituitary tissue: enhancement paterns on gadopentetate-enhanced MR imaging[J]. Radiology. 1990; 177 (1) : 35-38
3. Yuh WTC, Fisher DJ, Nguyen HD, etal. Sequential MRenhancement patern in normal pituitary gland and in pituitary adenomas[J]. American Journal of Neuroradiology. 1994; 15 (1) : 101-108.
4. Tharpar K, Scheithauer BK, Kovask K, etal. Proliferative activity and invasiveness among pituitary adenomas and carcinomas, an analysis using the MIB-1 antibody [J]. Neurosurgrey. 1996; 38 (1) : 99-106.
5. Selman WR Laws ER Jr. Scheithauer BW, etal. The occurrence of dural invasion in pituitary adenomas[J]. J Neurosurgery. 1986; 64 (3) : 402-407.
6. Vidal S, Kovacs K, Horvath E, etal. Microvessel density in pituitary adenomas and carcinoms[J]. Virchows Arch. 2001; 438(6)：595-602．
7．朱芳，周义成，王承缘，等。侵袭性垂体腺瘤的MRI和病理研究[J]。临床放射学杂志。2001：20 (9)：653-656．
8. Fraioli B. Esposito V. Palma L. Cantore G. Hemorrhagic pituitary adenomas: clinicopathological features and surgical treatment[J]. Neurosurgery. 1990; 27(5) : 741-7.
9. Post KD. Habas JE. Comparison of long term results between prolactin secreting adenomas and ACTH secreting adenomas [J]. Canadian Journal of Neurological Sciences. 1990; 17 (1) : 74-77.
10. Pegolo G, Buckwalter JG, Weiss MH, etal. Hinton DR. Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior [J]. Acta Cytolngica. 1995; 39 (5) : 887-892.
11. Pei L, Melmed S. Isolation and characterization of a pituitary tumor transformation gene (PTTG) [J]. Mole Endocrinol. 1997; 11 (4) : 433-441.
12. Zhang X, Horwitz ga, Heaney AP, etal. Pituitary tumor transforming gene(PTTG) expression in pituitary adenomas[J]. Clin Endocrinol Metab. 1999; 84 (2) : 761-767.
13. Hunter JA, Skelly RH, Aylwin SJ, etal. The relationship between pituitary tumor transforming gene expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas [J]. Eur J Endocrinol. 2003; 14(8): 203-211.
14. Yu R, Melmed S. Oncoge(?)e activation in pituitary tumor[J].Brain Pathology. 2001; 11 (30): 328-341.
15. Daita G, Yonermasu Y. Dural invasion and proliferative potential of pituitary adenomas[J]. Neurol Med Chir. 1996;36(4):211-214.
16. Mastronardi L, Guiducci A, Spera C, etal. Ki-67 labeling index and invasiveness among anterior pituitary adenomas:analysis of 1003 cases using the MIB-1 monoclonal antibody[J]. J Clin Pathol. 1999:52(1): 107-111.
17. Sakamoto H, Ukena K, Takemori H, etal. Expression and localization of 25-Dx, a membrane-associated putative progregesterone- binding protein, in the developing Purkinje cell[J]. Neuro- science. 2004; 126(2): 325-334.
18. Sanno N, Teramoto A, Osamure RY, etal. Pathology of pituitary tumor[J]. Neurosurg Clin N Am. 2003;14(1):25-39..
19. Lu CD, Altieri DC, Tanigawa N. Expression of novel antipoptosis gene, surviving, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas[J]. Cancer Res. 1998;58(9): 1802- 1812.
20. Takino H.Herman V,Wiss M, etal. Purine binding factor (nm23)gene expression in pituitary tumor:marker of adenomas invasiveness[J]. J Clin Endocrinol Metab. 1995;80(5):1733-1742.
21. Martin KK, Pilkinton GJ.Nm23:an invasion suppression gene in CNStumour[J].Anticancer Research. 1998;18(2A):919-926.
22. Wng LP, Brown JL, Eng C. PTEN coordinates G1 arrest by down-regulation cyclin D1 via protein phosphataseactivity and upregulation p27via tis lipid phosphatase activity in a breast cancer model[J]. Hun Mol Genet. 2001;21(10):599-604
23. Tumura M, Gu J, Tran H, etal. PTEN gene and integrin sigalling in cancer[J].Nat Cancer Inst. 1999;91(21):1820-1828.
24. Serrano M. INK4a/ARF locus in murine tumorigenesis[J]. Carcino genesis. 2000;21(10):865-869
25. Seemann N, Kuhn D, Wrocklage C, etal. CDKN2A/p16 inactivation is related to pituitary adenomas type and size[J]. J Pathol. 2001; 193(4): 491-497.
26. Reed AL, Califano J, Cairns P, etal. High frequent of pl6 (CDKN2/MTS- 1/INK4A) inactivation in head and neck squamous cell carcinoma[J]. Cancer Res. 1996;56(16):3630-3633.
27．余德蓉，易静，陈玉英，等。垂体腺瘤p16抑癌基因免疫组化和原位杂交德检测及与PCNA共表达的研究[J]。肿瘤。1999：19 (4)：202—205．
28. Boggild MD, Jenkinson S, Pistorello M, etal. Molecular genetic studies of sporadic pituitary tumor[J]. J Clin Endocrinol Metab. 1994; 78 (2) : 387-392.
29. Heaney AP, Horwitz GA, Wang Z, etal. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathologenesis[J]. Nat Med. 1999; 5 (11) : 1317-1321.
30. Mizoue T, Kacamoto H, Sebo TJ, etal. MIB-1 immunopositivity is associated with regrowth of pituitary adenomas[J]. Acta Neurochir. 1997; 13 (9) : 5-9.
31. Fisher BJ, Gaspar LE, Noone B. Giant pituitary adenomas: role of radiotherapy[J]. Int J Radia Oncol Biol Phy. 1993; 25 (4) : 677-681.
32. Grigsby PW. Stokes S. Marks JE. Simpson JR. Prognostic factors and results of radiotherapy alone in the management of pituitary adenomas[J]. International Journal of Radiation Oncology, Biology, Physics. 1988; 15 (5) : 1103-10.
33. Grigsby PW. Simpson JR. Emami BN. Fineberg BB. Schwartz HG. Prognostic factors and results of surgery and postoperative irradiation in the management of pituitary adenomas[J]. International Journal of Radiation Oncology, Biology, Physics. 1989;16(6):1411-1417.
34. Atkinson AB. Allen IV. Gordon DS. Hadden DR. Maguire CJ. Trimble ER. Lyons AR. Progressive visual failure in acromegaly following external pituitary irradiation [J]. Clinical Endocrinology. 1979; 10(5): 469-479.
35. Aloia JF. Archambeau JO. Hypopituitarism following pituitary irradiation for acromegaly[J]. Hormone Research. 1978; 9(4): 201-207.
36. Snyder PJ. Fowble BF. Schatz NJ. Savino PJ. Gennarelli TA. Hypopituitarism following radiation therapy of pituitary adenomas[J]. American Journal of Medicine. 1986;81 (3):457-462.
37. Kanaan IN. Minimally invasive approach to management of pituitary adenomas[J]. Minim Invasive Neurosurg. 2005;48(3):169-174.
38. Nomilos P, Buchfeelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure' [J]. Eur J Endocrinol. 2005;152(3):379-387.
39. Meij BP, Lopes MB, Ellegala DB, etal. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery[J].J Neurosurg. 2002; 96 (2): 195-202.
40. Zielinski G, Podgorski JK, Koziarski A, etal. Surgical treatment of invasive pituitary adenomas (somatotropinoma or cortico-\ tropinoma [J]. Neurol Neurochir Pol. 2003; 37(6): 1239-1255.
41. Visot A.Neurosurgery and pituitary tumors:surgical indications and outcome[J].Presse Med. 2001;30(8):401-404.
42. Chang CZ, Huang YH, Howng SL. Follow-up of invasive pituitary macroadenomas in 56 patients within a duration of 5 years[J]. Kaohsiung J Med Sci. 2000;16(7):339-344.
43. Izawa M, Hayashi M, Nakaya K, etal. Gamma knife radiosurgery for pituitary adenomas[J]. J Neurosurg.2000;93(suppl3):19-22.
44. Shin M, Kurita H, Sasaki T, etal. Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus [J]. J Neurosurg. 2000; 93(suppl 3): 2-5.
45. Losa M, Mortini P, Barzaghi R, etal. Surgical treatment of prolactin- secreting pituitary adenomas:early result and long-term outcome[J].J Clin Endocrinol Metab. 2002; 87(7): 3180-3186.
46. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary denomas and outcome in one surgical center[J]. Eur J Endocrinol. 2001; 145 (2) : 137-145
47．陈茂送，于春江。侵袭性垂体腺瘤的临床研究进展[J]。中国微侵袭神经外科杂志。2003；8 (7)：331—333。
2. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins[J].Cell. 1979; 16(4):885-893.
3. Senger DR, Wirth DF, Hynes R0. Transformation-specific secreted phosphoproteins[J]. Nature. 1980; 286(5773):619-621.
4. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein(osteopontin) cDNA reveals an Arg-Gly-Asp cell binding sequence[J]. Proc Natl Acad Sci USA. 1986; 83(23): 8819-8823.
5. Coppola D, Correlation of osteopontin protein expression and path — ological stage across a wide variety of tumorhistologies [J]. Clin Cancer Res. 2004 ; 10(1Pt1): 184-190.
6. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clini—cal and experimental studies[J]. J Mammary Gland Biol Neoplasia. 2001;6 (4) :419-429.
7. Ue T, Yokozaki H, Kitadai Y, etal. Co-expression of osteopontin and CD44v9 in gastric cancer[J].Int J Cancer. 1998;79 (2) :127-132.
8. Casson AG, Wilson SM, McCart JA, etal. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human eso — phageal cancer[J].Int J Cancer. 1997;72 (5) :739-745.
9. Thalmann GN,Sike RA, Devoll RE, etal.Osteopontin rpossible role in prostate cancer progress[J]. Clinical Cancer Res. 1999;5 (8) : 2271-2277.
10. Otte SJ, Winquist EW, Sititt L, etal. Plasma osteopontin associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma[J] .Cancer. 2002;95(3): 506-512。
11. Furger KA, Menon RK, Tuckl AB, etal. The functional and clinical roles of osteopontin in cancer and metastasis[J].Curr Ml Med.2001; 1(5): 621-632.
12. Tuck AB, O' Malley FP,Singhal H, etal. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas [J]. Arch Pathol Lab Med. 1997; 121(6):578-584.
13. Ye QH,Qin LX, Forgues M, etal. Predicting bepatitis B vinus-positive metastatic hepatocellular carcinomas using gene expression prof- iling and supervised machine learning[J]. Nature Med. 2003;9(4): 416-423.
14. Shijubo N, Uded T, Koo S, etal. Vascular endothelial growth factor and osteopontin in tumor biology[J].Crit Rev Oncog. 2000; 11 (2): 135-146.
15. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies[J].J Mammary Gland Biol Neoplasia. 2001;6(4):419-429.
16. Weinberger KM, Wiedenmann E, Bohm S,etal. Sensitive and accurate quan —titation of hepatitis B virus DNA using a kinetic fluorescence detection system(Taq Man PCR) [J]. J Virol Methods. 2000; 85 (1-2) : 75-82.
17. Eun AJ, Soeh M, Wong S, etal. Simultaneous quantitation of two orchid viruses by the Taq Man real-time RT-PCR[J]. J Virol Methods. 2000; 87 (1-2) : 151-160.
18．蒋春燕，王泰健，王琴。实时荧光定量PCR技术[J]。动物医学进展。2005：12 (1)：101—105。
1. Anderson RC, Grant JJ, de la Paz R, etal. Volumetric measurements in the detection of reduced ventricular volume in patients with normal pressure hydrocephalus whose clinical condition improved after ventriculoperitoneal shunt placement[J]. J Neurosurg.2002;97(1), 73-79.
2. Clatterbuck RE, Sipos EP. The efficient calculation of neurosurgically relevant volumes from computed tomographic scans using Cavalieri' s Direct Estimator[J]. Neurosurgery. 1997;40 (2) :339-343.
3. Medico E, Gentile A, Lo Celso C, etal. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth[J]. Cancer Res. 2001;61(15):5861-5868.
4. Shi jubo N, Uede T, Kon S, etal. Vascular endothelial growth factor and osteopontin in tumor biology[J].Crit Rev Oncog. 2000; 11(2): 135-146.
5. Denhardt DT, Chamber AF. Overcoming obstacles to metastasis defenses against host defences:osteopontin(OPN) as a shield against attack by cytotoxic host cells. J Cellular Biochem. 1994;56(1):48-51.
6. Vacca A, Ria R, Presta M, etal. Integrin alpha V beta 3 engagement modulates cell adehension, proliferation, and protease secretion in human lymphoid tumor cells[J]. Exp Hematol. 2001;29(8):993-1003.
7. Hotte S, Winquist EW, Stitt L, etal. Plasma osteopontin associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma[J]. Cancer. 2002; 95 (3) : 5. 6-512.
8．董俊峰，张占堆。51例颅内血肿量的新法计算探讨[J]。河南实用神经疾病杂志。2002：5 (2)：73-75．
9. Fucci MJ, Buchman CA, Brackmann DE, etal. Acoustic tumor growth: implica tions for treatment choices[J]. Am J Otol. 1999: 20 (4) : 495-499.
10. Tang Xi, HU Guoqing, Qiu Hong, etal. Comparing gross tumor volume of delineation between CT and MRI for nasopharygeal carcinoma[J]. The Chinese-German Journal of Clinical Oncology. 2005; 4 (3) : 141-145.
11. Thapar K, Kovacs K, Scheithauer BW, etal. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody[J]. Neurosurgery. 1996; 38 (1) : 99-106.
12. Honegger J, Prettin C, Feuerhake F, etal. Expression of Ki-67antigen in nonfunctioning pituitary adenomas: correl-ation with growth velocity and invasiveness[J]. J Neurosurgery. 2003; 99 (4) : 674-679.
13. Landolt AM, Shibata T, Kleihues P. Growth rate of human pituitary adenomas[J]. J Neurosurgery. 1987; 67 (6) : 803-806.
14. Lath R, Chacko G, Chandy MJ. Ditermination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody[J]. Neuro India. 2001; 49 (2) : 144-147.
15. Paez PM, Ledda MF, Goldberg V, et al. High levels of matrix metall oproteinases regulate proliferation and hormone secretion in pituitary cells [J]. J Clin Endocrinol Metab. 2000; 85 (1) : 263～269.
16．李玉斌，魏新亭，宋来君，等。基质金属蛋白酶-2和9在垂体腺瘤中表达[J]。中国临床神经外科杂志．2004：9 (6)：410-413．
17．刘卫平，章翔，松本义人，等。MMP-2及MMP-9表达在侵袭性垂体腺瘤中的生物学意义[J]。中华神经外科疾病研究杂．2004：3 (1)：47-51。
18. Hofmann UB, Westphal JR, Wass ET, etal. Coexpression of integrin alpha V beta 3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression[J]. J Invest Dermatol. 2000; 115 (4) : 625-632.
19. Silletti S, Kesster T, Goldberg J, etal. Disruption of matrix metalloproteinase 2 binding to integrin alpha V beta 3 by an organic molecule inhibites angiogenesis and tumor growth in vivo[J]. Proc Natl Acta Sci USA. 2001; 98 (1) : 119-124.
1. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy[J]. Biochim Biophys Acta. 2001; 1552(2): 61-85.
2. Furger KA, Alian AL, Wilson SM, etal. β_3 integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin[J].Mol Cancer Res. 2003;1(11): 810—819。
3. Liapis H, Flath A, Kitazawa S, etal. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases [J]. Diagn Mol Pathol. 1996; 5 (2): 127-135.
4. Hofmann UB, Westphal JR, Wass ET, etal. Coexpression of integrin alpha V beta 3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation:correlation with melanoma progression[J].J Invest Dermatol.2000;115(4):625-632.
5. Silletti S, Kesster T, Goldberg J, etal. Disruption of matrix metal1 oproteinase 2 binding to integrin alpha V beta 3 by an organic molecule inhibites angiogenesis and tumor growth in vivo[J].Proc Natl Acta Sci USA. 2001;98(1):119-124.
6. Liu W, Matsumoto Y, Okada M, etal. Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas[J].J Medical Investigation. 2005; 52(3-4): 151-158.
7. Paez PM,Ledda MF, Goldberg V, etal.High level of matrix metall oproteinases regulate proliferation and hormone secretion in pituitary cells[J]. J Clinical Endocrinology Metasbolism. 2000; 85(1): 263-269.
8. Khabit AM, Nip J, Fallavollita L, etal. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alpha V beta 3[J].Int Cance. 2001; 91(3) :300-308。
9. Mousa SA, Mohamed S, Wexler EJ, etal. Antiangiogenesis and anticancer efficacy of TA138, a novel alpha V beta 3 antagonist[J]. Anticancer Research. 2005;25(1A):197-206.
10. Paulus W, Baur I, Schupan D, etal. Characterization of integrin receptor in normal and neoplastic human brain[J].American journal of pathology. 1993;143(1):154-163.
1. Sodek J, Ganss B, Mckee MD. Osteopontin[J]. Crit Rev Oral Biol Med. 2000; 11 (3) : 279-303.
2. Chambers AF, Behrend EI, Wilson SM, etal. Induction of expression of osteopontin (OPN, secreted phosphoprotein) in metastatic, ras-transformed NIH 3t3 cells[J]. Anticancer Res. 1992; 12 (1) : 43-47.
3. Weber GF. The metastatic gene osteopontin: a candidate target for cancer therapy [J]. Biochim Biophys Acta. 2001; 1552 (2) : 61-85.
4. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cell signaling and toxicant injuring [J]. Annu Rev Pharmacol Toxical. 2001; 41 (5) : 723-749.
5. Crosby AH, Edwards SJ, Murray JC, etal. Genomic organization of the human osteopontin gene: exclusion of the locus from a causative role in the parhogenesis of dentinogenesis imperfecta type Ⅱ [J]. Genomics. 1995; 27 (1) : 155-160.
6. Sodek J, Zhu B, Huynh MH, etal. Novel functions of the matricellular proteins Osteopontin and osteonection/SPARC [J]. Connect Tisssue Res. 2002; 43 (2-3) : 308-319.
7. Haynes B, Teken M, Hale L, etal. CD44—a molecule involved in leukocyte asherence and T-cell activation[J]. Immunol Today. 1989; 10 (2) : 423-428.
8. Serenton G, Bell M, Jackson D, etal. Genomic structure of DNA encoding the lymphocyte homing receptor CD44reveals at least 12 alternatively spkiced exons[J]. Pro Natl Acad Sci USA. 1992; 89 (24) : 12160-12164.
9. Naor D, Sionov RV, Shalom DI. CD44: structure, function, and associatin with malignant process[J]. Adv Cancer Res. 1997; 71: 241-319.
10. Sneath R, Mangham D. The normal structure and function of CD44 and its role in neoplasia[J]. Mol Pathol. 1998; 51 (4) :191-200.
11．田文，张国华，谷志远，等。CD44异常表达与结肠直肠癌形成和转移的关系[J]。中华医学杂志。1997；77 (8)：72—73．
12. Ishida T. Immunohistochemical expression of the CD44variant 6 in colorectal adenocarcinoma[J]. Surh Today. 2000; 30 (1) : 28-32.
13. Ni HM, Leong AF, Cheong D, etal. Expression of CD44 variants in colorectal carcinoma quantified by real-time reverse transcriptasepolymerase chain reactin[J]. Lab Clin Med. 2002; 139 (1) : 59-65.
14. Koochekpour S, Pilkington G, Merzak A, etal. Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human gliomas cell in vitro[J]. Int J Cancer. 1995; 63 (3) : 450-454.
15. Kaai jk P, Troost D, Morsink F, etal. Expression of CD44 splice variants in human primary brain tumors[J]. J Neurooncol. 1995; 26 (3) : 185-190.
16. Li h, j Liu Hofmann M, etal. Differential CD44 expression paterns in primary tumors and brain metastasis[J]. Br J Cancer. 1995; 72 (1) : 160-163.
17．段波，赵红洋，李新建，等。细胞黏附分子CD44s，CD44v5在垂体腺瘤中的表达及其意义[J]。现代肿瘤医学。2005；13 (4)：466—468。
18. Frank S, Rihs HP, Stocker W, etal. Combined dectection of CD44 ISOFORMS BY EXON-SPECIFIC rt-PCR and immunohistochemistry in primary human brain tumors and brain metastases[J]. Biochem Biophys Res Commun. 1996; 222 (3) : 794—801。
19. Kuniyasu H, Chihara Y, Kubozoe T, etal. Co-expression of CD44v3 and heparanase is correlated with metastasis of human colon cancer [J]. Int J Mol Med. 2002; 10 (3) : 333-337.
20. Hamidi S, Salo T, Kainulainen T, etal. Expression of alpha (v) beta 6 integrin in oral leukoplakia[J]. Br J Cancer. 2000; 82 (8) : 1433-1440
21. Kim S, Bell K, Mousa SA, etal. Regulayion of angiogenesis in vivo byligation of integrin alpha 5 beta with the central cell-binding domain of fibronection[J]. Am J Pathol. 2000; 156 (4) : 1345-1362
22. Grooms SV, Terrsacio L, Jones LS, etal. Anatomical localization of beta 1 integrin-like immunoreactivity in rat brain[J]. Experimental Neurology. 1993;122(2):253-259.
23. Carloni V, Mazzocca A, Pantaleo P. etal. The integrin alpha 6 beta 1, is necessary for the matrix-dependeng activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells [J]. Hepatology. 2001; 34(1): 42-49.
24. Thomas GJ, Lewis MP, Whawell SA, etal. Expression of the alpha v beta 6 intefrin promtes migration and invasion in squamous carcinoma cell[J].J Invest Dermatol.2001;117(1):67-73.
25. Abdel-Ghany M, Cheng HC, Elble RC, etal. The breast cancer beata 4 integrin and endothelial heman CLC A2 mediated ;ing metastasis [J]. J Biol Chem.2001; 276(27):25438-25446.
26. Daemi N, Thomasset N, Lissitzky JC, etal. Anti-beta 4 integrin antibodies enhance migratory and invasive abilities of human colon adenocarcinomas cells and their MMP-2 expression[J]. Int J Cancer. 2000:85(6):850-856.
27. Kok RJ, Schraa AJ, Bassi R, etal. Preparation and functional evaluation of RDG-modified proteins as alpha (v) beta (3) integrin drectod therapeutics[J].Bioconjugate Chemistry. 2002;13(1):128-135.
28. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis [J]. Cancer Journal. 2000;6(suppl 3):245-249.
29. Humphries MJ. The molecular basis and specificity of integrin-ligand interactions[J].J Cell Sci. 1990;97(pt 47):585-592.
30. Zhang J, Takahashi K, Takahashi F,etal. Differential osteopontin expression in lung cancer[J].Cancer Lett.2001;171(2):215-222.
31. Tuck AB, Chambers AF. The role of osteopontin in breast cancer:clinical and experimental studies[J].J Mammary Gland Biol Neoplasis. 2001;6(4): 419-429.
32. Gotoh M, Sakamoto M, Kanetaka K, etal. Over expression of osteopontin in hepatocellular carcinomas[J].Pathol Int.2002;52(1):19-24.
33. Denhardt DT, Mistretta D, Chambers AF, etal. Transcriptional regulation of osteopontin and the metastatic phenotype:evidence for a ras-activated enhancer in the human OPN promoter[J].C1in Exp Metastasis. 2003;20(1):77-84.
34. Singhal H, Bautista DS, Tonkin KS, etal. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival[J].C1in Cncer Res. 1997;3(4):605-611.
35. Yeatman TJ, Chamber AF. Osteopontin and colon cancer progression [J]. Clin Exp Metastasis. 2003;20(1):85-90.
36. Hotte SJ, Winquist EW,Stitt L, etal. Plasm osteopontin associations with survival and metastasis to bone in mean with hormone-refractory prostate carcinoma. Cancer. 2002;95(3):506-512.
37. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metallo proteinase-2 activation through I kappa alpha/IKK signaling pathways, and curcumin(diferulolylmethane) down- regulates these pathways[J].J Biol Chem.2003;278(16):14487-14497.
38. Mahabeleshwar GHD, Kunda GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transaction in breat cancer cells[J].J Biol Chem.2004;279(12):11051-11064.
39. Coppola D, Szabo M, Boulware D. Correlatin of osteopontin protein expression and pathological atge across a wide variety of tumor histologies[J].Clin Cancer Res.2004;10(1):184-190.
40. Hotte SJ, Winquist EW, Stitt L, etal. Plasma osteopontin associations with survival and matastasis to bone in men with hormong-refractory prostate carcinoma[J]. Cancer. 2002;95(3):506-512.
41. Barry STMLudbrook SB, Murrison E, etal. A regulated intergration between alpha 5 beta 1 integrin and osteopontin[J]. Biochem Biophys Res Commun. 2000;267 (3); 764-769。
42. Katagiri YU.Sleeman J,Fujii H, etal.CD44 variants but not CD44s cooperated with beta 1-containing integrins to permit cell bind to osteopontin independ of argine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis[J]. Cancer Res. 1999; 59 (1) : 219-226.
1. Knosp E. Steiner E. Kitz K etal. Pituitary adenomas with invasion of the cavernoussinus space: A magnetic resonance imaging classification compared with surgical findings [J]. Neurosurgery. 1993; 33 (4) : 610-617
2. Miki Y, Maisuo M, Nishzawa S, etal. Pituitary adenomas and normal pituitary tissue: enhancement paterns on gadopentetate-enhanced MR imaging[J]. Radiology. 1990; 177 (1) : 35-38
3. Yuh WTC, Fisher DJ, Nguyen HD, etal. Sequential MRenhancement patern in normal pituitary gland and in pituitary adenomas[J]. American Journal of Neuroradiology. 1994; 15 (1) : 101-108.
4. Tharpar K, Scheithauer BK, Kovask K, etal. Proliferative activity and invasiveness among pituitary adenomas and carcinomas, an analysis using the MIB-1 antibody [J]. Neurosurgrey. 1996; 38 (1) : 99-106.
5. Selman WR Laws ER Jr. Scheithauer BW, etal. The occurrence of dural invasion in pituitary adenomas[J]. J Neurosurgery. 1986; 64 (3) : 402-407.
6. Vidal S, Kovacs K, Horvath E, etal. Microvessel density in pituitary adenomas and carcinoms[J]. Virchows Arch. 2001; 438(6)：595-602．
7．朱芳，周义成，王承缘，等。侵袭性垂体腺瘤的MRI和病理研究[J]。临床放射学杂志。2001：20 (9)：653-656．
8. Fraioli B. Esposito V. Palma L. Cantore G. Hemorrhagic pituitary adenomas: clinicopathological features and surgical treatment[J]. Neurosurgery. 1990; 27(5) : 741-7.
9. Post KD. Habas JE. Comparison of long term results between prolactin secreting adenomas and ACTH secreting adenomas [J]. Canadian Journal of Neurological Sciences. 1990; 17 (1) : 74-77.
10. Pegolo G, Buckwalter JG, Weiss MH, etal. Hinton DR. Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior [J]. Acta Cytolngica. 1995; 39 (5) : 887-892.
11. Pei L, Melmed S. Isolation and characterization of a pituitary tumor transformation gene (PTTG) [J]. Mole Endocrinol. 1997; 11 (4) : 433-441.
12. Zhang X, Horwitz ga, Heaney AP, etal. Pituitary tumor transforming gene(PTTG) expression in pituitary adenomas[J]. Clin Endocrinol Metab. 1999; 84 (2) : 761-767.
13. Hunter JA, Skelly RH, Aylwin SJ, etal. The relationship between pituitary tumor transforming gene expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas [J]. Eur J Endocrinol. 2003; 14(8): 203-211.
14. Yu R, Melmed S. Oncoge(?)e activation in pituitary tumor[J].Brain Pathology. 2001; 11 (30): 328-341.
15. Daita G, Yonermasu Y. Dural invasion and proliferative potential of pituitary adenomas[J]. Neurol Med Chir. 1996;36(4):211-214.
16. Mastronardi L, Guiducci A, Spera C, etal. Ki-67 labeling index and invasiveness among anterior pituitary adenomas:analysis of 1003 cases using the MIB-1 monoclonal antibody[J]. J Clin Pathol. 1999:52(1): 107-111.
17. Sakamoto H, Ukena K, Takemori H, etal. Expression and localization of 25-Dx, a membrane-associated putative progregesterone- binding protein, in the developing Purkinje cell[J]. Neuro- science. 2004; 126(2): 325-334.
18. Sanno N, Teramoto A, Osamure RY, etal. Pathology of pituitary tumor[J]. Neurosurg Clin N Am. 2003;14(1):25-39..
19. Lu CD, Altieri DC, Tanigawa N. Expression of novel antipoptosis gene, surviving, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas[J]. Cancer Res. 1998;58(9): 1802- 1812.
20. Takino H.Herman V,Wiss M, etal. Purine binding factor (nm23)gene expression in pituitary tumor:marker of adenomas invasiveness[J]. J Clin Endocrinol Metab. 1995;80(5):1733-1742.
21. Martin KK, Pilkinton GJ.Nm23:an invasion suppression gene in CNStumour[J].Anticancer Research. 1998;18(2A):919-926.
22. Wng LP, Brown JL, Eng C. PTEN coordinates G1 arrest by down-regulation cyclin D1 via protein phosphataseactivity and upregulation p27via tis lipid phosphatase activity in a breast cancer model[J]. Hun Mol Genet. 2001;21(10):599-604
23. Tumura M, Gu J, Tran H, etal. PTEN gene and integrin sigalling in cancer[J].Nat Cancer Inst. 1999;91(21):1820-1828.
24. Serrano M. INK4a/ARF locus in murine tumorigenesis[J]. Carcino genesis. 2000;21(10):865-869
25. Seemann N, Kuhn D, Wrocklage C, etal. CDKN2A/p16 inactivation is related to pituitary adenomas type and size[J]. J Pathol. 2001; 193(4): 491-497.
26. Reed AL, Califano J, Cairns P, etal. High frequent of pl6 (CDKN2/MTS- 1/INK4A) inactivation in head and neck squamous cell carcinoma[J]. Cancer Res. 1996;56(16):3630-3633.
27．余德蓉，易静，陈玉英，等。垂体腺瘤p16抑癌基因免疫组化和原位杂交德检测及与PCNA共表达的研究[J]。肿瘤。1999：19 (4)：202—205．
28. Boggild MD, Jenkinson S, Pistorello M, etal. Molecular genetic studies of sporadic pituitary tumor[J]. J Clin Endocrinol Metab. 1994; 78 (2) : 387-392.
29. Heaney AP, Horwitz GA, Wang Z, etal. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathologenesis[J]. Nat Med. 1999; 5 (11) : 1317-1321.
30. Mizoue T, Kacamoto H, Sebo TJ, etal. MIB-1 immunopositivity is associated with regrowth of pituitary adenomas[J]. Acta Neurochir. 1997; 13 (9) : 5-9.
31. Fisher BJ, Gaspar LE, Noone B. Giant pituitary adenomas: role of radiotherapy[J]. Int J Radia Oncol Biol Phy. 1993; 25 (4) : 677-681.
32. Grigsby PW. Stokes S. Marks JE. Simpson JR. Prognostic factors and results of radiotherapy alone in the management of pituitary adenomas[J]. International Journal of Radiation Oncology, Biology, Physics. 1988; 15 (5) : 1103-10.
33. Grigsby PW. Simpson JR. Emami BN. Fineberg BB. Schwartz HG. Prognostic factors and results of surgery and postoperative irradiation in the management of pituitary adenomas[J]. International Journal of Radiation Oncology, Biology, Physics. 1989;16(6):1411-1417.
34. Atkinson AB. Allen IV. Gordon DS. Hadden DR. Maguire CJ. Trimble ER. Lyons AR. Progressive visual failure in acromegaly following external pituitary irradiation [J]. Clinical Endocrinology. 1979; 10(5): 469-479.
35. Aloia JF. Archambeau JO. Hypopituitarism following pituitary irradiation for acromegaly[J]. Hormone Research. 1978; 9(4): 201-207.
36. Snyder PJ. Fowble BF. Schatz NJ. Savino PJ. Gennarelli TA. Hypopituitarism following radiation therapy of pituitary adenomas[J]. American Journal of Medicine. 1986;81 (3):457-462.
37. Kanaan IN. Minimally invasive approach to management of pituitary adenomas[J]. Minim Invasive Neurosurg. 2005;48(3):169-174.
38. Nomilos P, Buchfeelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure' [J]. Eur J Endocrinol. 2005;152(3):379-387.
39. Meij BP, Lopes MB, Ellegala DB, etal. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery[J].J Neurosurg. 2002; 96 (2): 195-202.
40. Zielinski G, Podgorski JK, Koziarski A, etal. Surgical treatment of invasive pituitary adenomas (somatotropinoma or cortico-\ tropinoma [J]. Neurol Neurochir Pol. 2003; 37(6): 1239-1255.
41. Visot A.Neurosurgery and pituitary tumors:surgical indications and outcome[J].Presse Med. 2001;30(8):401-404.
42. Chang CZ, Huang YH, Howng SL. Follow-up of invasive pituitary macroadenomas in 56 patients within a duration of 5 years[J]. Kaohsiung J Med Sci. 2000;16(7):339-344.
43. Izawa M, Hayashi M, Nakaya K, etal. Gamma knife radiosurgery for pituitary adenomas[J]. J Neurosurg.2000;93(suppl3):19-22.
44. Shin M, Kurita H, Sasaki T, etal. Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus [J]. J Neurosurg. 2000; 93(suppl 3): 2-5.
45. Losa M, Mortini P, Barzaghi R, etal. Surgical treatment of prolactin- secreting pituitary adenomas:early result and long-term outcome[J].J Clin Endocrinol Metab. 2002; 87(7): 3180-3186.
46. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary denomas and outcome in one surgical center[J]. Eur J Endocrinol. 2001; 145 (2) : 137-145
47．陈茂送，于春江。侵袭性垂体腺瘤的临床研究进展[J]。中国微侵袭神经外科杂志。2003；8 (7)：331—333。